


# GERD / BARRETT'S ESOPHAGUS



Barrett's Esophagus is the only known precursor of EAC<sup>1</sup>

Esophageal cancer is the

**fastest growing cancer<sup>2</sup>...**



...where

**4 out of 5 patients**

**die within 5 years<sup>3</sup>**

**1 in 4 cases of EAC**



is diagnosed within 1 year of normal index endoscopy in patients with BE<sup>4</sup>




## CELLVIZIO® CLINICAL VALUE

**Better targeting of biopsies to improve your diagnostic yield<sup>5,6</sup>**

**Rule-in or rule-out intestinal metaplasia with 98% sensitivity and 96% NPV<sup>7</sup>**

**2x DETECTION of dysplastic lesions from 34% to 68%<sup>5</sup>**

## REAL-TIME IN VIVO CELLULAR IMAGING IMAGE PATTERN RECOGNITION





## SOCIETY SUPPORT

"CLE is a promising adjunct to standard surveillance programs for BE given its ability for in vivo assessment of mucosal tissue analysis"<sup>8</sup>

The SAGES Technology and Value Assessment Committee

**Cellvizio®**  
SEE CELLS. CHANGE LIVES.

# CELLVIZIO® SOLUTION



## INTEGRATE CELLVIZIO® INTO YOUR PRACTICE

"Cellvizio® makes it possible for us to: rule-in or rule-out the presence of pre-cancerous cells (...) perform improved surgical intervention (...) monitor for the presence of cancerous cells after the procedure"

**Dr. J. Burnette,**  
Coliseum Northside Hospital

Image interpretation confidence can be gained within months.<sup>9</sup>

"Cellvizio® is very useful in the clinical management of my patients, and is supported by dedicated CPT codes."

**Dr. K. Ayub,**  
Silver Cross Hospital

## IMPROVE PATIENT MANAGEMENT

### CHRONIC GERD SYMPTOMS

Rule-in or rule-out intestinal metaplasia<sup>7</sup>, allowing early detection of Barrett's<sup>9</sup>

**CANCER**  
pCLE can lead to positive redirection of therapy<sup>12</sup>



**MANAGEMENT OF BARRETT'S**  
pCLE provides a significantly higher diagnostic yield and reduces sampling error compared to random four-quadrant biopsies<sup>10</sup>

### DYSPLASIA

Define location and lateral extent of neoplasia inducing clinical intervention<sup>11</sup>



### GastroFlex™ UHD Miniprobe

Compatible operating channel  
≥ 2.8 mm

Length  
3 m

Number of uses per probe  
20

Field of view  
Ø240 µm

Resolution  
1 µm

Working distance  
60 +/- 15 µm

\* Courtesy of Dr. Samaraseena. <sup>1</sup> Bhardwaj A. et al. Barrett's Esophagus: Emerging Knowledge and Management Strategies. Pathology Research International, 2012. <sup>2</sup> Chai J. et al. Esophageal malignancy: A growing concern, World Journal of Gastroenterology, 2012. <sup>3</sup> Desai M. et al. Prevalence of HGD and adenocarcinoma on index endoscopy in BE, Gastrointest Endosc, 2018. <sup>4</sup> Visrodia K. et al. Magnitude of Missed Esophageal Adenocarcinoma After Barrett's Esophagus Diagnosis: A Systematic Review and Meta-analysis. Gastroenterology, 2016. <sup>5</sup> Sharma P. et al. Real-time increased detection of Neoplastic tissue in Barrett's Esophagus with pCLE: Final results of a multi-center prospective international randomized controlled trial, Gastrointest Endosc, 2011 (DONT BIOPCE). <sup>6</sup> Canto M. et al. In vivo endomicroscopy improves detection of Barrett's Esophagus related neoplasia: a multicenter international randomized controlled trial, GIE, 2013. <sup>7</sup> Kiesslich R. et al. In vivo histology of Barrett's Esophagus and Associated Neoplasia by CLE, Clinical Gastro and Hepatology, 2006. <sup>8</sup> Al-Mansour. et al. SAGES TAVAC safety and efficacy analysis confocal laser endomicroscopy. Surg Endosc (2020). <sup>9</sup> Richardson C. et al. Real-time diagnosis of Barrett's Esophagus: a prospective, multicenter study comparing confocal laser endomicroscopy with conventional histology for the identification of intestinal metaplasia in new users, Surgical Endoscopy, 2018. <sup>10</sup> DeMeester S. et al. High definition probe-based confocal laser endomicroscopy review and meta-analysis for neoplasia detection in Barrett's esophagus. Techniques and Innovations in Gastrointestinal Endoscopy, 2022. <sup>11</sup> Wang K. et al. Use of probe-based confocal laser endomicroscopy (pCLE) in gastrointestinal applications. A consensus report based on clinical evidence. UEG Journal, 2015. <sup>12</sup> Caillol et al. Probe confocal laser endomicroscopy in the therapeutic endoscopic management of Barrett's dysplasia. Annals of Gastroenterology, 2017.

Cellvizio® I.V.E. with Confocal Miniprobess™ are regulated Medical Devices, CE marked (CE 0459) (Class IIa - NB : G-MED) and FDA cleared. Cellvizio® is a registered trademark and Confocal Miniprobe™ is a trademark of Mauna Kea Technologies. Cellvizio® I.V.E. with Confocal Miniprobess™ is a confocal laser system with fiber optic probes that is intended to allow imaging of the internal microstructure of tissues including, but not limited to, the identification of cells and vessels and their organization or architecture. Once connected to the Cellvizio® I.V.E.: The GastroFlex™ UHD and ColoFlex™ UHD Confocal Miniprobess™ are intended to allow imaging of anatomical tracts, i.e., gastrointestinal systems, accessed by an endoscope or endoscopic accessories. Please consult labels and instructions for use. These statements and the associated reference to specific clinical studies, are not intended to represent claims of safety or effectiveness for detecting or treating any specific condition or disease state. Rather this information is intended to provide useful reference to selected published literature describing physician experiences with the associated clinical uses. Any diagnostic assessment should always be made by the attending physician, based on the evaluation of all sources of clinical, endoscopic and other relevant information. These statements have not been reviewed, cleared, or approved by the U.S. FDA. The use of this medical device is exclusively reserved for health professionals. Product availability cannot be guaranteed in all countries. For further information, please contact your local sales representative.